Apurva Harsh Vira

@apurva.harsh.vira.3462

Thane

5+ Years of experience

SEBI Registration INH000024064

Trade Ideas

Opinions

Followers

Expertise

Quantitative

Technical

Index Strategies

Market Commentary

Futures & Options

Technical Analysis

Trade Facts

Total Trades

Missed Trades

Profit Trades

Accuracy

Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 6 hours ago

JSW Dulux GST Demand Cut 64% to ₹42 Crore

JSWDULUX

formerly known as Akzo Nobel India, has received an order from the Karnataka GST Department reducing its tax demand by approximately 64.5%, from ₹118.33 crore to ₹42.04 crore. The dispute relates to the disallowance of Input Tax Credit (ITC) for FY21. The original show-cause notice, issued in August 2026, included ₹40.09 crore in tax, ₹38.18 crore in interest and ₹40.07 crore in penalties. Following the company's response and supporting documentation, the revised demand stands at ₹14.07 crore in tax, ₹13.90 crore in interest and ₹14.07 crore in penalties. The total reduction of ₹76.29 crore represents a significant decrease in the company's potential tax liability. However, the dispute remains unresolved, and JSW Dulux is preparing further submissions to the authorities. From a research perspective, the reduction is a positive development as it lowers the company's potential financial exposure. However, it does not directly improve operating revenue or profitability, and the final financial impact will depend on the outcome of the proceedings. The stock closed at ₹3,058.60 on October 19, declining 0.45%, suggesting that the announcement did not trigger an immediate positive market reaction. Investors should monitor further regulatory developments, potential provisions and the company's upcoming quarterly financial results. Learning Takeaway: A reduction in tax demand lowers potential financial risk but does not automatically increase earnings. Investors should distinguish between operational improvements and one-time regulatory developments when evaluating a company. Disclosure: This post is for educational purposes only and does not constitute investment advice. Any holdings or conflicts of interest should be disclosed separately.

102

shared an insight ⚡️ 9 hours ago

Sobha Q2 Profit Falls 55% Despite Strong Sales Growth

SOBHA

reported weak Q2 FY27 financial results, with consolidated net profit declining 54.5% YoY to ₹32.96 crore from ₹72.53 crore. Revenue from operations fell 31.3% to ₹967.06 crore, compared with ₹1,407.66 crore in the corresponding quarter last year. EBITDA declined to ₹68.73 crore from ₹101.64 crore, reflecting lower revenue recognition and pressure on operating profitability. However, the company's operational performance tells a different story. Sobha recorded its highest-ever H1 FY27 sales value of ₹5,862 crore, growing 47.2% YoY. Q2 sales bookings stood at ₹2,206 crore, up approximately 16% YoY, while average realisation improved 13.7% to ₹15,522 per sq. ft. The company also has a strong project pipeline of 20.42 million sq. ft., with an estimated sales potential of ₹31,353 crore. Additionally, revenue yet to be recognised from already-sold units stands at approximately ₹22,041 crore, providing future revenue visibility. From a research perspective, the difference between strong property sales and declining reported revenue is important. Real estate companies generally recognise revenue based on project completion and applicable accounting requirements, creating a timing gap between bookings and reported earnings. Investors should monitor project completions, revenue recognition, operating margins, cash collections and debt levels. Delays in project execution could affect future profitability despite healthy bookings. Learning Takeaway: In real estate, strong sales bookings do not immediately translate into reported revenue or profits. Investors should evaluate project execution, collections and unrecognised revenue alongside quarterly earnings. Disclosure: This post is for educational purposes only and does not constitute investment advice. Any holdings or conflicts of interest should be disclosed separately.

149

shared an insight ⚡️ 19th Oct

Natco Pharma Launches Cancer Drug in US Market

NATCOPHARM

has announced the launch of Carboplatin Injection, a generic version of Paraplatin, in the US market through its subsidiary Natco Pharma USA LLC. The product is manufactured in collaboration with Chennai-based Teyro Labs Pvt Ltd. Carboplatin Injection is used in the treatment of advanced ovarian cancer, including first-line combination therapy and treatment of recurrent disease. The launch comes amid a critical shortage of the drug in the US, creating an opportunity for Natco to address existing demand. According to industry sales data, Carboplatin Injection recorded approximately $27.8 million in US sales during the 12 months ended June 2026. This represents the overall product market size, not Natco's expected revenue. From a research perspective, the launch strengthens Natco's oncology portfolio and its presence in the US generics market. The company already has an established international pharmaceutical business, with US revenue of approximately ₹2,381 crore in FY26. The ongoing drug shortage could support initial demand. However, the financial contribution will depend on market share, product pricing, manufacturing capacity and competition from existing suppliers. Investors should monitor US sales traction, product margins, supply availability and future oncology launches. Generic drug prices can face pressure as competition increases, even when initial demand is strong. Learning Takeaway: A pharmaceutical product launch creates a revenue opportunity, but market size does not equal company revenue. Investors should evaluate market share, competition, pricing and profitability before estimating its earnings impact. Disclosure: This post is for educational purposes only and does not constitute investment advice. Any holdings or conflicts of interest should be disclosed separately.

556

What are the top stock recommendations by Apurva Harsh Vira?

Apurva Harsh Vira regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include JSWDULUX, SOBHA and NATCOPHARM. Explore Apurva Harsh Vira's complete list of posts and trade views on their StockGro profile.

How can I follow Apurva Harsh Vira's latest investment insights?

You can follow Apurva Harsh Vira's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

What is Apurva Harsh Vira's investment strategy?

Apurva Harsh Vira follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

How long has Apurva Harsh Vira been a SEBI-registered Research Analyst (RA)?

Apurva Harsh Vira has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

Where can I see Apurva Harsh Vira's past performance and stock picks?

You can check Apurva Harsh Vira's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

How can I contact Apurva Harsh Vira for stock market advice?

For stock market guidance from Apurva Harsh Vira, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

What is Apurva Harsh Vira's track record in predicting market movements?

Apurva Harsh Vira has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

What is the SEBI Registration number for Apurva Harsh Vira?

Apurva Harsh Vira is a SEBI-registered Research Analyst with the SEBI Registration INH000024064. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.

Be Financially Free with StockGro